Biological and Mechanical Properties of Denture Base Material as a Vehicle for Novel Hydroxyapatite Nanoparticles Loaded with Drug

Asmaa Nabil Elboraey1, Hanan Hassan Abo-Almaged2, Ahmed Abd El-Rahman El-Ashmawy1, Aya Rashad Abdou3, Amani Ramadan Moussa1, Laila Hassanian Emara1, Hossam Mohammed El-Masry4, Gehan El-Tabie El Bassouyi2, Magda Ismail Ramzy1

1Fixed and Removable Prosthodontics Department, National Research Centre, 33 El Buhouth Street, Dokki, P.O.12622 Cairo, Egypt.
2Refractories, Ceramics and Building Materials Department, National Research Centre, 33 El Buhouth Street, Dokki, P.O.12622, Cairo, Egypt.
3Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, 33 EL Bohouth st. (former EL Tahrir st.), Dokki, Giza, Egypt, P.O.12622, Affiliation ID: 10014618.
4Chemistry of Natural Microbial Products Department, National Research Centre,33 El Buhouth Street, Dokki, P.O.12622, Cairo, Egypt.

Introduction

The need for removable prostheses will continue due to the increase in human aged population. Poly(methyl methacrylate) (PMMA) is the denture based material of choice for more than 50 years and up to now owing to its applicable mechanical, physiochemical, and working properties.

However, denture PMMA may be colonized by some microorganisms such as Candida albicans, Streptococcus mutans and Staphylococcus aureus. Such oral pathogens may contribute to oral infections as denture stomatitis, systemic infections and pneumonia. Denture cleansers alone are ineffective against denture plaque removal and also, may cause significant damage to dentures. Systemic antibiotic has been specified for management of oral infections; however, excessive use of systemic drugs led to the development of microbial resistant strains. On the other hand, the topical application of antibiotics may be ineffective due to its inability to maintain physical contact with oral mucosal tissue, limiting anatomical features of the oral cavity as well as constant washing effect caused by the salivary flow. Therefore, there is a need for...

Abstract

Purpose: This study aimed to evaluate the biological and mechanical properties of the poly(methyl methacrylate) (PMMA) denture base material as a vehicle incorporating novel hydroxyapatite nanoparticles (HA-NP) loaded with metronidazole (MZ) drug.

Methods: HA-NP was prepared via wet-chemical-method, characterized by XRD, SEM/EDX, TEM, Fourier-transform infrared spectroscopy (FTIR), as well as the measurement of surface area and pore-size distribution. Four drug delivery formulas were prepared in the form of discs (10 x 2 mm) as follows: F1 (MZ/HA-NP/PMMA), F2 (HA-NP/PMMA), F3 (control-PMMA) and F4 (MZ/PMMA). Characterization of all formulas was performed using differential scanning calorimetry (DSC) and FTIR. MZ release rate, antimicrobial properties against three oral pathogens, cytotoxicity (MTT assay) and surface micro-hardness were also assessed. Statistical analysis of data was performed using one-way ANOVA test (P < 0.05).

Results: DSC thermograms showed compatibility among MZ, HA-NP and PMMA along with physical stability over 6 months storage period at room temperature. FTIR spectroscopy proved the absence of any possible chemical interaction with MZ. MZ-HA-NP/PMMA formula showed relatively better drug release compared to MZ-PMMA. Both formulas showed statistically significant antimicrobial potentials against two microbial strains. MTT demonstrated reduction in cell cytotoxicity after 96 hours with the least value for HA-NP. Surface micro-hardness revealed non-significant reduction compared with the control PMMA.

Conclusion: A novel biocompatible drug nanocarrier (HA-NP) was developed and incorporated in PMMA denture base material as a vehicle to allow prolonged sustained drug release to manage oral infections.
a technology that permits controlled drug delivery with optimal concentration at the required site.\(^8\)

Recently, the introduction of nanoparticle-based drug delivery technologies allows an effective and targeted drug delivery without undesirable side effects. The therapeutic applications of drug delivery include cancer therapy, antimicrobial actions and vaccine delivery. Such technology is more appropriate to patients as it does not require frequent application regimes. In addition, direct delivery of the drug to the site of infection reduces the risk of systemic side effects or drug-drug interactions.\(^9,10\)

For a material to be used as a drug carrier, it must have the ability to carry a drug either physically or chemically. Drug carrier must preserve the drug until it reaches the targeted site, being progressively degraded, and deliver the drug in a controllable manner over time. Generally, drug nano-carriers were classified into non-biodegradable and biodegradable. Nanocarriers biodegradable category includes collagen, sponges, or inorganic nanoparticles as calcium phosphate.\(^11,12\) Hydroxyapatite exists naturally in the body, as a major constituent of bone and tooth enamel, which accounts for their superior biocompatibility and biodegradability.\(^13,14\)

In literature, incorporation of different antimicrobial agent into denture base resins such as: chlorhexidine, local antibiotics and nanomaterials as nano-silver, nano-titanium dioxide, or nano-silicon dioxide have been extensively studied.\(^15,16\) Meanwhile, the use of PMMA as vehicle for drug nanocarriers to ensure sustained release of drug and to control oral infection in removable prostheses was investigated by Mohamed Hamouda.\(^17\)

Therefore, the aim of the present study was to develop and formulate biodegradable hydroxyapatite nanoparticles (HA-NP) as a nanocarrier for metronidazole (MZ) as a model drug using PMMA resin as a vehicle to manage the oral infection.

**Materials and Methods**

**Materials**

1. Diammonium hydrogen phosphate, Merck, Germany
2. Calcium nitrate tetrahydrate (extra pure), Acros, New Jersey, USA
3. Ammonia hydroxide, LOBA Chemie, Mumbai, India
4. Chemically activated PMMA (Acrostone, dental and medical suppliers, industrial zone, Cairo -Egypt)
5. Metronidazole, (Batch No: 0181901176, HUANGGANG, HUBEI PROVINCE, CHINE.)
6. HEPES Buffer (Lot No: S17706L0180, Serox GmbH, Mannheim, Germany)
7. Sodium Azide, (Batch No: L215501802, LOBA CHEMIE PVT.LTD Mumbai, India.)
8. Potassium bromide (Lot# BcBW6864, Sigma Aldrich, Germany)
9. Dulbecco’s Modified Eagle’s Medium Ham’s F-12 (DMEM/F12) cell culture medium (Lonza, Veries, Belgium).

**Preparation and characterization of HA-NP**

HA-NP was prepared via wet chemical method by the reaction between calcium nitrate tetra hydrate and diammonium hydrogen phosphate.\(^11\) The stoichiometric ratio of calcium nitrate \([\text{Ca(NO}_3\text{)]}_4\text{H}_2\text{O}]\) and diammonium hydrogen phosphate \([\text{(NH}_4\text{)]}_2\text{HPO}_4]\) was adjusted to obtain a final \((\text{Ca/P})\) molar ratio at about 1.68. HA was precipitated as a milky gelatinous precipitate through the slow addition of the \((0.6\text{M})\) of \((\text{NH}_4\text{)]}_2\text{HPO}_4\) to \((1\text{M})\) of \([\text{Ca(NO}_3\text{)]}_4\text{H}_2\text{O}]\) while stirring. To adjust the pH of the mixture at 11, ammonium hydroxide \((\text{NH}_4\text{OH})\) solution was gradually added. The precipitate was left to be digested under reflux for 1 hour at 65°C, washed to remove the \(\text{NH}_4^+\) and \(\text{NO}_3^-\) and then separated by centrifugation. The obtained powder was dried overnight at 110°C. The resulting amorphous product was calcined in an electrical furnace at 500°C for 2 hours at a heating rate of 10°C/min in air.

To identify the crystalline phases of the HA powder, X-rays diffraction analysis was applied using XRD \([\text{Bruker D8 Advance, Germany}], \text{Cu-Kα} \text{ radiation (λ = 0.15418 nm), Ni filter. XRD diffractometer operated at 40 kV and 40 mA over a 2θ range of 10°-70°. Likewise, the crystallinity and nanoparticle nature of the HA powder were examined by high resolution transmission electron microscope (HR-TEM) model (JEOL JEM-2100, Japan). TEM samples were prepared by dispersing HA-NP in distilled water then, processed in an ultrasonic transducer for 30 minutes. A single drop of the prepared suspension was drop-casted onto a carbon-coated copper grid, air dried at room temperature for 40 minutes, before being microscopically analyzed.\(^18\)

To study the crystal morphology, microstructure details and elemental analysis of the prepared nano powder, scanning electron microscopy (SEM) model FEI, QUANTA, FEG, 250 equipped with energy dispersive X-ray analysis unit (EDX) was used. Samples were sputter coated with a thin film of gold to ensure a high quality image. Fourier transform infrared spectroscopy (FT/IR-6100) was used to examine the chemical composition and define the functional groups using the KBr pellet technique over the range of 400–4000 cm\(^{-1}\). The Barrett-Emmett-Teller method was employed to determine the surface area of the prepared HA powder. It was carried out by Nitrogen adsorption-desorption isotherm (Bel Sorb Max device from BEL, Japan INC). Total pore volume was calculated using the single point adsorption method at relative pressure of \((p/p_0 = 0.932)\). Furthermore, the pore size distribution was estimated using mercury porosimeter (Pore Size, Micromeritics model 9320, USA).

**Preparation and characterization of local delivery formulas**

**Preparation of PMMA local delivery disc specimens**

Chemically activated PMMA (Acrostone, dental and
medical suppliers, industrial zone, Cairo, Egypt) supplied in the form of polymer powder and monomer liquid was selected for this study. PMMA was used as vehicle for both MZ and nanocarrier loaded with MZ. For control PMMA (F3), the disc of dimension (10 mm diameter X 2 mm thickness) were manually prepared by mixing powder to monomer according to manufacture (2.8 mg polymer powder/ 1.2 mL liquid monomer). When dough stage was reached, the mixture was packed into a specially fabricated hexagonal stainless-steel molds, with inner detachable Teflon rings and sandwiched between two glass slabs then allowed to polymerize for 15 minutes. Other three PMMA drug delivery discs were prepared by incorporating different weight percentages of MZ, HA-NP and combination of MZ and HA-NP to the PMMA polymer powder as shown in Table 1.

Then the monomer was added to PMMA powder, thoroughly mixed following previous procedure to obtain the three drug formulas.

Characterization of PMMA local delivery discs

Differential scanning calorimetry (DSC): DSC was performed for pure MZ, PMMA, HA-NP and crushed discs of each batch to detect possible chemical interactions between the drug and the excipients employed in disc formulations. DSC 131 evo (SETARAM Inc., France) was used to implement the differential scanning calorimeter analysis. DSC instrument was calibrated using the standards (Mercury, Indium, Tin, Lead, Zinc and Aluminum). Nitrogen and helium were used as purging gases. Test was programmed starting from 25-250°C. 120 μL of the samples were weighted in an aluminum crucible and introduced into the DSC. The sample was heated up to 250°C at a heating rate of 10°C/min. Thermogram results were processed using (CALISTO Data processing software v.1.49).

Fourier transform-infrared (FTIR) Analysis: FTIR spectra were obtained using FT-IR-6100 spectrometer (Jasco, Japan). The samples (pure MZ, PMMA, HA-NP and crushed discs of each batch) were ground and mixed thoroughly with potassium bromide (KBr), an infrared transparent matrix, at the ratio of 1:5 (sample/KBr), respectively. The KBr disks were prepared by compressing the powders at a pressure of 5 tons for 5 min in a hydraulic press. Scans were obtained at a resolution of 4 cm⁻¹, from 4000 cm⁻¹ to 400 cm⁻¹.

Stability study: Prepared discs were stored on bench under ambient conditions, in a tightly closed containers away from direct sunlight. After 6-months, the stored discs were analyzed using DSC and Fourier-transform infrared spectroscopy (FTIR) and compared to fresh samples.

Assessment of release of metronidazole from different local delivery discs

Discs containing MZ drug (F1 and F4) were individually immersed in 5 mL buffer (artificial saliva) containing physiological concentrations of electrolytes in saliva (0.7 mole/L CaCl₂, 2.6 mole/L MgCl₂, 0.2 mole/L H₂O, 4.0 mole/L KH₂PO₄, 30 mole/L KCl, 0.3 mole/L Na₂S₂O₃, 20 mole/L of HEPES buffer) with slight viscosity at neutral pH. The specimens were shoked at 37°C and 40 RPM using Temperature-controlled shaking water-bath, Lab-Line, Dubuque, IA, USA. The artificial saliva was daily replaced. Periodically, the quantity of drug released from each specimen was determined by UV spectrophotometry (UV-Visible spectrophotometer, Beckman, DU-650, USA) measurements at λ_max = 321 nm. Each test was repeated 5 times and MZ release profile was tested for a one month period.

Antimicrobial assessment of the PMMA local delivery discs

The antimicrobial properties of the two prepared discs containing MZ (F1 and F4) were assessed using shaking flask method. Discs were soaked in 5.0 mL artificial saliva and incubated in a shaker incubator at 37°C for different periods of 2, 4 and 8 days. Three pathogenic Gram-positive bacterial strains were tested including: *Staphylococcus aureus* (ATCC 6538), *Enterococcus faecalis* (ATCC 19433) and *Streptococcus mutans* (ATCC 25175). The antibacterial test was performed quantitatively using standard test method according to the AATCC test method 100-1999 for Bacterial Counting. Each bacterial strain was individually inoculated into 5 mL BHI (brain heart infusion broth) sterile suspension. The suspension and compared to fresh samples.

Antibacterial activity was expressed in reduction (%) of the organisms after getting in contact with the test specimen compared with the number of the organism cells surviving after contact with the control (F3). The percentage of pathogenic microorganism reduction after contact with the tested formulas was measured using spectrophotometer (Perkin-Elmer Lambda EZ 201 UV-Vis-USA) and compared with control bacterial strain. All results were expressed according to the following equation:

\[
\text{Reduction} \% = (A - \frac{B}{A}) \times 100
\]

| Formula Code | Disc Composition (% w/w) |
|--------------|--------------------------|
|              | MZ | HA-NP | PMMA |
| F1           | 10 | 10    | 80   |
| F2           | 0  | 10    | 90   |
| F3 (control) | 0  | 0     | 100  |
| F4           | 10 | 0     | 90   |

Table 1. PMMA Local Drug Delivery Discs
A: The number of microorganisms present on control flask contains bacterial strain only without any thing.
B: The number of microorganisms present on shake flask after applying tested micro-organism samples.

**Cytotoxic assessment of different PMMA local delivery discs**

The potential cytotoxicity of different drug delivery discs (F1, F2, and F4) as well as the control one (F3) were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay test. The test was conducted on human normal fibroblast cell (BJ1) in Bioassay-Cell Culture Laboratory (National Research Centre, Cairo, Egypt). All test steps were performed in a laminar flow cabinet biosafety class II level (Baker, SG403INT, Stanford, ME, USA). Each formula was immersed in 100 mL of Dulbecco's Modified Eagle's Medium Ham's F-12 (DMEM/F12) cell culture medium (1:1 MIX Lonza, Veries, Belgium) for 24, 48 and 96 hours. Cytotoxicity of the specimen elutes were assessed, after each immersion period. The BJ1 cells were suspended in DMEM/F12, 1% antibiotic-antimycotic mixture (10000 U/mL potassium penicillin, 10000 μg/mL Streptomycin Sulfate and 25μg/mL Amphotericin B) and 1% L-glutamine at 37°C under 5% CO₂. Cells were batch cultured for 10 days and seeded at concentration of 10 x 10⁴ cells/well in a new growth medium into 96-well microtiter plastic plates at 37°C for 24 hours under 5% CO₂ using water jacketed carbon dioxide incubator (Sheldon, TC2323, Cornelius, OR, USA).

After 24 hours the media was replaced with equal volumes of elute materials from both composite specimens' and tissue conditioning. For negative control, cells were incubated in DMEM/F12 alone. Although, positive control 100 μg/mL of a natural agent of known cytotoxic effects (100% lethality) under the same conditions was used. 25,26

After 48 hours of incubation, the medium was replaced with 40 ul MTT salt (2.5 μg/mL) and incubated for further 4 hours at 37°C under 5% CO₂. To stop the reaction and dissolve the formed crystals, 200 μL of the 10% sodium dodecyl sulphate in deionized water was added then incubated overnight at 37°C. Absorbance was measured using a microplate multi-well reader (Bio-Rad Laboratories Inc., model 3350, Hercules, California, USA) at 595 nm and a reference wavelength of 620 nm. The percentage of change in viability was calculated according to the formula:

\[
\text{Percentage viability} = \left( \frac{\text{Reading of specimens}}{\text{Reading of negative control}} \right) - 1 \]  

\[
(2)
\]

**Surface micro-hardness of PMMA local delivery discs**

36 specimens of F1, F2, control F3 and F4 (n = 9) were prepared to measure the surface micro-hardness using Vicker's hardness testing machine (Nexus 4503, INNOVATEST, Netherlands, Europe). A 100 g load was applied for 30 seconds with 20X magnification. Every disc was subjected to three indentations (one on the center and two on the borders) and the average value was recorded. 19

**Statistical analysis**

Data were analyzed using IBM® SPSS® (SPSS Inc., IBM Corporation, USA) statistics version 23 for Windows. One-way repeated measures ANOVA test followed by Tukey’s post hoc was used for comparison between different formulas and during the follow up periods within each formula. The significant difference was set at (P < 0.05)

**Results and Discussion**

**Characterization of HA-NP**

The crystal phase composition of the prepared hydroxyapatite powder was determined using the X-ray diffraction (XRD) pattern (Figure 1). Peak matching was done by comparing respective 2θ values to standard peak values in the International Centre for Diffraction Data (ICDD) cards of HA standard pattern. Results revealed the presence of all major HA peaks at 2θ ~ 31.8°, 28~32.7° and 34.2° in a good agreement with the ICDD standard pattern for the hydroxyapatite (JCPDS card no. 76-0694). The absence of peaks at 2θ =17-18° and 19-21° prove the lack of other secondary phases such as CaO and α-TCP, respectively. 12 TEM micrographs of the synthesized HA-NP powder were shown in (Figure 2a & b). The average particle size of the HA grains was in the nano range of 11-36 nm (Figure 2a). The grains appeared in a nano-rod morphology; with uniform size aggregated together in the form of clusters, (Figure 2b). Ikeda et al proposed that the rod-shaped HA crystals in bone substitute applications are more favored, owing to the effective osteoclast homing activity and local bone metabolism of the rod-shaped HA crystals. 27 EDX analysis for the HA-NP powder was shown in (Figure 2d). Ca/P ratio was around 1.59. SEM micrograph displayed in (Figure 2c), showed a uniform and homogeneous microstructure network with very fine agglomerate particles in the nanometer size range between 30-56 nm. Particles displayed porous and interconnected morphology consequently, signifying it can be used for bone tissue engineering applications. 28 The functional groups of the HA-NP powder were identified using the FTIR spectrum (Figure 3). Bands at 3433 cm⁻¹ and 1632 cm⁻¹, related to the OH stretching and bending vibrations, respectively. The strong band at 1039 cm⁻¹ was attributed to the symmetric stretching vibrations of νPO₄³⁻ group. Characteristic bands indicative of bending vibration of νPO₄³⁻ appeared as a doublet at 604 and 569 cm⁻¹,29,30 The carbonate bands detected at 1450 and 875 cm⁻¹ assigned to the stretching and bending vibrations of the CO₂⁻ ion owing to the incorporation of CO₂⁻ groups for the PO₄³⁻ sites in the structure. 31 These groups may have been adsorbed from the atmosphere by the HA during
the synthesis process. In this study, the FTIR spectra matched to those reported by previous authors and are consistent with the XRD results. The prepared HA-NP showed a surface area of 131.9 (m$^2$/g). Total pore volume was 0.1014 cm$^3$/g, whereas the total pore size distribution of the prepared HA-NP ranged between 9-14 nm with a mean pore diameter of 11.2 nm.

**Characterization of PMMA local delivery disc specimens**

Chemically cured resin was selected to ease manipulation, since it requires no special equipment. As well as to standardize the laboratory procedures during the preparation of different drug formulas thus eliminating possible lab technician inaccuracies. Four drug delivery formulas were prepared F1 (MZ/HA-NP/PMMA), F2 (HA-NP/PMMA), F4 (MZ/PMMA), in addition to F3 (control/PMMA). Only 10% weight percentage of MZ drug powder was added to PMMA since this weight percentage had no detrimental effect on the properties of the PMMA. Similarly, 10% weight of HA-NP powder was also incorporated into PMMA. For F1 drug formula the maximum weight% of MZ and HA-NP added to PMMA without affecting manipulation characteristics of the PMMA resin was found to be 20%.

**DSC analysis**

DSC measures the heat loss or gain resulting from physical or chemical changes within a sample as a function of temperature. Any possible drug - excipients interactions in the drug formulation could be predicted by conducting the DSC studies. Figure 4a showed the DSC thermograms of MZ, PMMA, HA-NP, crushed prepared discs (fresh and 6-month stored samples). A single sharp endothermic peak appeared at 166ºC represents the melting point of pure MZ. The appearance of the characteristic MZ melting endothermic peak in the prepared discs indicated absence of any possible interaction from PMMA (Figure 4a). The peak intensity of MZ in the discs showed a decrease in comparison with the sole drug, regarding the dilution effect of the formulation components. For drug sample and MZ-containing discs (F1 and F4 discs), the thermograms did not show any significant shift in endothermic peaks neither in the fresh nor in the stored discs. Based on the thermograms of DSC, there is no possibility of interactions between MZ and the proposed excipient. The prepared discs were physically stable over the 6 months storage period at room temperature.

**FTIR analysis**

The possibility of occurrence of any drug-excipients interactions in a drug formulation was also predicted by conducting the FTIR studies. Figure 4b showed the FTIR spectra of MZ, PMMA, HA-NP, crushed prepared discs (fresh and 6-months stored samples). Figure 4b showed the principle fingerprint of FTIR absorption bands for MZ at 3223, 3100, 1535 and 1370 cm$^{-1}$ which recognizes the presence of C-H stretching, C=CH stretching, N-O stretching and NO$_2$ symmetric stretching, respectively, in addition two strong characteristic bands at 1269 and 1188 cm$^{-1}$ corresponding to O-H in the plan deformation
PMMA as a vehicle for HA nanocarrier loaded with metronidazole

and C-O stretching, respectively.\(^{41}\) The FTIR spectra of both the fresh and 6-month stored drug loaded discs (F1 and F4) exhibited all the characteristic bands as in the spectrum of the individual MZ excluding the possibility of any interaction (Figure 4b). Also, chemical and functional group changes during processing of the formulation of drug loaded discs were excluded.\(^{42}\) There was neither origin of any new characteristic peaks nor absence of any original characteristic peaks which revealed no incompatibility between drug and excipients even after storage.\(^{43}\) The appearance of the characteristic MZ bands indicated absence of any possible chemical interaction during formulation and storage.

**Drug release**

The antibacterial drug contained in the disc specimens, namely, MZ (20 mg/disc), demonstrated an initial high rate of release (burst effect) from the surface of PMMA discs during the first 3 days (22.06 % and 19.55 % for F1; HA-NP/PMMA discs and F4; PMMA discs, respectively) followed by a slower sustained release profile up to 30 days (31.59 % and 25.53 % for F1 and F4 discs, respectively) as shown in Figure 5a.\(^{44-46}\) MZ release profiles showed a biphasic release phenomenon. The first phase gave high amounts of drug released followed by a second phase of sustained release profile with a much lower release amount Figure 5b. The highest amount of MZ released was recorded on the second day (1794.62 µg and 1568.63 µg for F1 and F4 discs, respectively). Conferring to Dhana Lekshmi et al.,\(^{46}\) the drug content which is closer to the surface of the particles was responsible for an increased initial burst and the drug in the core of particles is responsible for a prolonged drug release from the polymer.\(^{47}\) It is worthy to mention that the incorporation of HA-NP within the PMMA discs was able to relatively improve the MZ release from the resin discs, however resulting in a similar release profiles as depicted by the calculated “Similarity factor” (\(f_2\)) value, whose value was 67. The dissolution profiles of F1 and F4 were compared by calculating the similarity factor (\(f_2\)) as proposed by Moore and Flanner\(^{48}\) which was defined using the following equation:

\[
f_2 = 50 \log \left\{ 1 + \left( \frac{1}{n} \right) \sum_{t=1}^{n} \frac{W_t(R_t - T_t)^2}{100} \right\}^{0.5}
\]

(3)

Where, \(R_t\) is the percentage of released drug for a reference batch at time point \(t\), \(T_t\) is the percentage of released drug for the test batch, \(n\) is the number of pull points collected during the in vitro release test, \(R\) and \(T\) are the cumulative percentages release at the selected time point of the two tested formulae. The Food and Drug

![Figure 4](image1.png)

**Figure 4.** (a) DSC thermograms of MZ, PMMA, HA-NP, crushed prepared discs (fresh and 6-month stored samples). (b) FTIR spectra of MZ, PMMA, HA-NP, crushed discs (fresh and 6-month stored samples).

![Figure 5](image2.png)

**Figure 5.** (a) MZ release profiles from PMMA discs in artificial saliva. (b) Amount of MZ released from PMMA discs in artificial saliva.

Advanced Pharmaceutical Bulletin, 2021, Volume 11, Issue 1 | 91
Administration (FDA) set a public standard of $(f_{2})$ value of 50-100 to indicate similarity between two dissolution profiles $(f_{2})$.\textsuperscript{50} Future studies for tailoring the MZ resin discs in such a way to improve the release profile will be considered. Our strategies will be focusing on increasing polymer hydrophilicity by synthesizing functionalized PMMA microspheres or by formulating PMMA composites with higher ratios of hydrophilic polymers.

**Antimicrobial effect of the different local delivery discs**

Figure 6 showed the percentage of bacterial reduction of the tested drug formulas (F1 and F4). Although, the results demonstrated reduction in mean value of the tested strains over time reaching the maximum reduction percentages after 8 days. Comparison between F1 and F4 mean values showed no statistically significant difference $(P>0.05)$ except for *Enterococcus faecalis*. Wherever, F4 showed higher statistically significant mean value only after two days and the result was statistically significant $(P<0.05)$.

Regarding the antimicrobial activity of each drug formula, F1 demonstrated reduction in mean values after 2, 4 and 8 days. However, the results were not statistically significant $(P>0.05)$ except against *Enterococcus faecalis* $(P<0.05)$. Although, F4 showed reduction in the mean value percentages, the results were statistically insignificant $(P>0.05)$ expect for *Streptococcus mutans* $(P<0.05)$

Results demonstrated sustained gradual release of MZ drug from the two formulas (F1 and F4). Such outcome demonstrated that polymerization of the PMMA resin did not adversely affect the release of drug nor altering the diffusion characteristics of the resin. This finding was in agreement with previous studies that utilized polymers for delivering antimicrobial agent.\textsuperscript{51,52}

The increase in the percentage of bacterial reduction when the elution of different drug formulas was added to each bacterial strain with time indicated that leaching behavior of MZ from each drug formal into artificial saliva was governed by a concentration dependent diffusion process.\textsuperscript{35}

**Cytotoxic effect of the different local delivery discs**

The cytotoxic effect of the different formulas and control were shown in Figure 7. Comparison of the cell cytotoxicity mean values revealed that F1, F2, F4 and control F3 had cytotoxic effects and the results were statistically significant $(P<0.05)$ after 24 hours. Where F4 revealed highest cytotoxic mean values followed by F1, F3 and the least mean value was for F2.

After 48 hours. There was reduction in cell cytotoxicity mean values and the results were statistically significant $(P<0.05)$. Again, the highest statistically significant mean value was recorded for F4 followed by F1, F3 and the least mean value was for F2 $(P<0.05)$.

Further reduction in cytotoxicity was evident after 96 hours. Wherever F1 showed highest mean value followed by F4, then F3 and finally F2 and results were statistically significant $(P<0.05)$.

The initial high cytotoxic effect of F1, F3 and F4 after 24 and 48 hours could be attributed to the leached unreacted PMMA monomer as documented in literature.\textsuperscript{53,54} For F4 this effect is coupled with the spurt release of MZ drug. On the other hand, F2 showed initially better biocompatibility compared to other formulas. The addition of 10% of HA-NP could possibly act as filler that primarily delayed the leaching of monomer in the first 24 and 48 hours. This was followed by a negligible increase in cytotoxicity.\textsuperscript{50} Such
assumption also may explain the reduced cytotoxicity of F1 compared to F4 formula after 24 and 48 hours. Following 96 hours there was slight decrease in the mean values of all formulas and control indicating the cell recovery and reduction in cell cytotoxicity to the acceptable levels as reported by Chen et al.55

Surface microhardness of different local delivery discs

Hardness is an important surface property used to predict the resistance of any dental material to penetrate and resist wear.56 The incorporation of MZ drug and nanocarriers to PMMA resin resulted in slight decrease in the surface hardness. Comparison of the surface microhardness of the control F3 (control PMMA) and three formulas F1, F2, and F4 were presented in Table 2. F3 showed higher mean value followed by F2 then F4 and the lowest value was for F1. However, there was no statistical significance difference between the control and tested formulas (P > 0.05).

This alteration in the hardness could be attributable to the decrease in polymer powder ratio in relation to the monomer content. The presence of excessive unreacted monomer adversely affects the mechanical properties due to its plasticizing effect that decreases the interchain forces and allowing the deformation to occur easily under load.57

Conclusion

A novel drug delivery nanocarrier (HA-NP) was successfully developed that allowed sustained release of MZ drug over a prolonged period up to 1 month. The developed nanocarrier was compatible physically and chemically with the MZ drug and PMMA denture base material.

Removable dental prosthesis fabricated from PMMA can be used as a vehicle for drug nanocarriers for management of oral infections. PMMA can incorporate additives up to 20% w/w (10% MZ and 10% HA-NP) without significantly altering the surface micro-hardness.

This study deserves to be extended with the same materials and additional excipients for better performance.

Ethical Issues

This study was designed and approved by the Medical Research Ethical committee (MREC Approval No. 16085) of National Research Centre (NRC), Cairo-Egypt.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

We would like to thank Dr. Sherihan M. Eissa Researcher of removable prosthodontics for her efforts in preforming the statistics of this research. This research was financially supported by National Research Centre (NRC), Cairo, Egypt (Project grant no. PI1010201).

References

1. Carlsson GE, Omar R. The future of complete dentures in oral rehabilitation. A critical review. J Oral Rehabil 2010;37(2):143-56. doi: 10.1111/j.1365-2842.2009.02039.x
2. Matsuo H, Suehara H, Takahashi M, Suzuki O, Sasaki K, Takahashi N. Deterioration of polymethyl methacrylate dentures in the oral cavity. Dent Mater J 2015;34(2):234-9. doi: 10.4012/dmj.2014-089
3. Phoenix RD, Mansou M, Ackerman NA, Jones RE. Evaluation of mechanical and thermal properties of commonly used denture base resins. J Prosthet Dent 2004;83(3):216-21. doi: 10.1111/j.1365-2842.2004.02039.x
4. Compagnoni MA, Pero AC, Ramos SM, Marra J, Paleari AG, Rodriguez IS. Antimicrobial activity and surface properties of an acrylic resin containing a biocide polymer. Gerodontology 2014;31(3):220–6. doi: 10.1111/ger.12031
5. Kiesow A, Sarembe S, Pizziy RL, Aae AS, Bradshaw DJ. Material compatibility and antimicrobial activity of consumer products commonly used to clean dentures. J Pros dent Dent 2016;115(2):189-98.e8. doi: 10.1016/j.jprospondent.2015.08.010
6. Ramage G, Jose A, Coco B, Rajendran R, Autemamaa R, Murray C, et al. Commercial mouthwashes are more effective than azole antifungals against Candida albicans biofilms in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111(4):456-60. doi: 10.1016/j.tripleo.2010.10.043
7. Webb BC, Thomas CJ, Willcox MD, Harty DW, Knox KW. Candida-associated denture stomatitis. Aetiology and management: a review. Part 1. Factors influencing distribution of Candida species in the oral cavity. Aust Dent J 1998;43(1):45-50. doi: 10.1111/j.1365-2842.1998.tb00152.x
8. Diez-Escudero A, Espanol M, Ginebra MP. Chapter 5 - Synthetic bone graft substitutes: Calcium-based biomaterials. In: Dent Implants and Bone Grafts. Woodhead Publishing; 2020. p. 125-57. doi: 10.1016/b978-0-08-102478-2.00006-4
9. Badr-Mohammadi MR, Hesaraki S, Zamanian A. Mechanical properties and in vitro cellular behavior of zinc-containing nano-bioactive glass doped biphasic calcium phosphate bone substitutes. J Mater Sci Mater Med 2014;25(1):185-97. doi: 10.1007/s10856-013-5062-7
10. Pashley DH, Tay FR, Yui C, Hashimoto M, Breschi L, Carvalho RM, et al. Collagen degradation by host-derived enzymes during aging. J Dent Res 2004;83(3):216-21. doi: 10.1177/154405910408300306
11. Radwan MM, Abd El-Hamid HK, Abo-Almaged HH, Salem HN, Omar N. Evaluation of calcium aluminate/
calcium phosphate based bio-cements as root-end filling material. Orient J Chem 2017;33(6):2692-706. doi: 10.13005/ojc/330602
12. Beherei HH, El-Bassyouni GT, Mohamed KR. Modulation, characterization and bioactivity of new biocomposites based on apatite. Ceram Int 2008;34(8):2091-7. doi: 10.1016/j.ceramint.2007.08.003
13. LeGeros RZ. Calcium phosphate-based osteoinductive materials. Chem Rev 2008;108(11):4742-53. doi: 10.1021/cr800427g
14. Bandopadhyay A, Bernard S, Xue W, Bose S. Calcium phosphate-based resorbable ceramics: influence of MgO, ZnO, and SiO2 dopants. J Am Ceram Soc 2006;89(9):2675-88. doi: 10.1111/j.1551-2916.2006.01207.x
15. Bertolini MM, Portela MB, Curvelo JA, Soares RM, Lourenço EJ, Telles DM. Resins-based denture soft lining materials modified by chlorhexidine salt incorporation: an in vitro analysis of antifungal activity, drug release and hardness. Dent Mater 2014;30(8):793-8. doi: 10.1016/j.dental.2014.05.004
16. Moussa AR, El-Kady AM, Elboraei AN, Zaki DY, El gamaly HM, El-Bassyouni GT, et al. Antimicrobial properties of the tissue conditioner containing silver doped bioactive glass nanoparticle: in vitro study. Advances in Natural Sciences: Nanoscience and Nanotechnology 2018;9(3):035003. doi: 10.1088/2043-6254/aad1a5
17. Mohamed Hamouda I. Current perspectives of nanoparticle in medical and dental biomaterials. J Biomed Res 2012;26(3):143-51. doi: 10.7555/jbr.26.20120027
18. Beherei HH, Mohamed KR, El-Bassyouni GT. Mechanical and bioactivity properties of nano ceramic composite-based oxyapatite materials. Interacer - International Ceramic Review 2014;63(7):386-92. doi: 10.1007/bf03401090
19. Zarb GA, Bolender CL, Carlsson GE. Boucher’s Prosthodontic Treatment for Edentulous Patients. 7th ed. Mosby; 1997. p. 338.
20. Paul SJ, Schärer P. The shear bond strengths of dentin-bonding agents under intrapulpal pressure and temperature changes. An in vitro study. Schweiz Monatsschr Zahnmed 1993;103(6):709-714.
21. Baum K, Kempf K, Hein HJ, Schubert J, Maurer P. Preservation of microelastic properties of dentin and tooth enamel in vitro--a scanning acoustic microscopy study. Dent Mater 2007;23(10):1221-8. doi: 10.1016/j.dental.2006.11.009
22. Cao Z, Sun X, Yeh CK, Sun Y. Rechargeable infection-responsive antifungal denture materials. J Dent Res 2010;89(12):1517-21. doi: 10.1177/0022034510379604
23. Chun DTW, Fouk IA, McAlister DD. Testing for antibacterial properties of cotton/flax denim. Ind Crops Prod 2009;29(2-3):371-6. doi: 10.1016/j.indcrop.2008.07.009
24. Abdelghaffar F, Abdelghaffar RA, Arafa AA, Kamel MM. Functional antibacterial finishing of woolen fabrics using ultrasound technology. Fibers Polym 2018;19(10):2103-11. doi: 10.1007/s12221-018-1056-x
25. Thabrew MI, Hughes RD, McFarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 1997;49(11):1132-5. doi: 10.1111/j.2042-7158.1997.tb06055.x
26. El-Menshawi BS, Fayad W, Mahmoud K, El-Hallouy SM, El-Manawy M, Olofsson MH, et al. Screening of natural products for therapeutic activity against solid tumors. Indian J Exp Biol 2010;48(3):258-64.
27. Ikeda T, Kasai M, Tatsukawa E, Kamitakahara M, Shibata Y, Yokoi T, et al. A bone substitute with high affinity for vitamin D-binding protein--relationship with niche of osteoclasts. J Cell Mol Med 2014;18(1):170-80. doi: 10.1111/jcmn.12180
28. Sun L, Berndt CC, Gross KA, Kucuk A. Material fundamentals and clinical performance of plasma-sprayed hydroxyapatite coatings: a review. J Biomed Mater Res 2001;58(5):570-92. doi: 10.1002/jbmr.1056
29. Stuart B. Modern Infrared Spectroscopy. Dartford: John Wiley and Sons; 1996. p. 105-11.
30. Arami H, Mohajerani M, Mazloumi M, Khalifehzadeh R, Lak A, Sadrnezhaad SK. Rapid formation of hydroxyapatite nanostrips via microwave irradiation. J Alloys Compd 2009;469(1-2):391-4. doi: 10.1016/j.jallcom.2008.01.116
31. Engin A, Girgin İ. Synthesis of hydroxyapatite by using calcium carbonate and phosphoric acid in various water-ethanol solvent systems. Cent Eur J Chem 2009;7(4):745-51. doi: 10.2478/s11532-009-0063-6
32. Chen JD, Wang YJ, Wei K, Zhang SH, Shi XT. Self-organization of hydroxyapatite nanorods through oriented attachment. Biomaterials 2007;28(14):2275-80. doi: 10.1016/j.biomaterials.2007.01.033
33. Wang YZ, Fu Y. Microwave-hydrothermal synthesis and characterization of hydroxyapatite nanocrystallites. Mater Lett 2011;65(23-24):3388-90. doi: 10.1016/j.matlet.2011.07.095
34. Mohamed KR, Beherei HH, El Bassyouni GT, El Mahallawy N. Fabrication and mechanical evaluation of hydroxyapatite/oxyde nano-composite materials. Mater Sci Eng C Mater Biol Appl 2013;33(7):4126-32. doi: 10.1016/j.msec.2013.05.059
35. Patel MP, Cruchley AT, Coleman DC, Swai H, Braden M, Williams DM. A polymeric system for the intra-oral delivery of an anti-fungal agent. Biomaterials 2001;22(17):2319-24. doi: 10.1016/S0142-9612(00)00367-7
36. Mori K, Tsuji M, Ueda T, Sakurai K. Color and gloss evaluation of titanium dioxide coating for acrylic resin denture base. J Prosthodont Res 2015;59(4):249-53. doi: 10.1016/j.jpor.2015.06.001
37. Prasannaraju Y, Asuntha G, Satyanadam S, Ramana Murthy KY. A study on physical characterization of Hupu gum, a natural polysaccharide for pharmaceutical use. J Innov Trends Pharma Sci 2011;2(6):174-83.
38. Devraj, Bhatt DC. Studies on enteric coated sustained timed-release tablets of Metronidazole. J Chem Pharm Res 2010;2(2):226-32.
39. Emara LH, Abdou AR, El-Asmawy AA, Mursi NM. Preparation and evaluation of metronidazole sustained release floating tablets. Int J Pharm Sci 2014;6(9):198-204.
40. Chaturvedi K, Umadevi S, Vaghani S. Floating matrix dosage form for propanolol hydrochloride based on gas formation technique: development and in vitro evaluation. Sci Pharm 2010;78(4):927-39. doi: 10.3797/scipharm.0909-02
41. Ramukutty S, Ramachandran E. Crystal growth by solvent technique: development and in vitro evaluation. Sci Pharm 2010;78(4):927-39. doi: 10.3797/scipharm.0909-02
42. Amarnath S, Damodaran H. Nanoparticle Synthesis and Characterization. J Cryst Growth 2012;351(1):47-50. doi: 10.1016/j.jcrysgro.2012.04.017
42. Purushothaman M, Vijaya RJ. Formulation optimization and release kinetics of Metronidazole matrix, compression and spray coated tablets: effect of organic acid on colon targeted drug delivery system. *Int J Res Pharm Sci* 2010;1(4):551-62.

43. Khan ZA, Tripathi R, Mishra B. Floating elementary osmotic pump tablet (FEOPT) for controlled delivery of diethylcarbamazine citrate: a water-soluble drug. *AAPS PharmSciTech* 2011;12(4):1312-23. doi: 10.1208/s12249-011-9969-6

44. Bettencourt A, Florindo HF, Ferreira IF, Matos A, Monteiro J, Neves C, et al. Incorporation of tocopherol acetate-containing particles in acrylic bone cement. *J Microencapsul* 2010;27(6):533-41. doi: 10.3109/02652048.2010.484106

45. Dhana Lekshmi UM, Poovi G, Kishore N, Reddy PN. In vitro characterization and in vivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. *Int J Pharm* 2010;396(1-2):194-203. doi: 10.1016/j.ijpharm.2010.06.023

46. Matos A, Castro M, Almeida AJ, Bettencourt A. *Incorporation of Minocycline into Poly(Methylmethacrylate) Drug Delivery Systems*. Proceedings of the 7th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 2010; Valletta, Malta.

47. Liu Z, Zhao G, Yu J, Zhang J, Ma X, Han G. Preparation and properties of chitosan-graft-poly(methyl methacrylate) nanoparticles using potassium diperoxytricarbonate (III) as an initiator. *J Appl Polym Sci* 2011;120(5):2707-15. doi: 10.1002/app.33436

48. Yuksel N, Baykara M, Shirinzade H, Suzen S. Investigation of triacetin effect on indomethacin release from poly (methyl methacrylate) microspheres: evaluation of interactions using FT-IR and NMR spectroscopies. *Int J Pharm* 2011;404(1-2):102-9. doi: 10.1016/j.ijpharm.2010.11.011

49. Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. *Pharm Technol* 1996;20(6):64-74.

50. Anderson NH, Bauer M, Boussac N, Khan-Malek R, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles. *J Pharm Biomed Anal* 1998;17(4-5):811-22. doi: 10.1016/s0731-7085(98)00011-9

51. Nasr I, De Rosa A, De Gregorio V, Grassia V, Donnarumma G. A new controlled-release material containing metronidazole and doxycycline for the treatment of periodontal and peri-implant diseases: formulation and in vitro testing. *Int J Dent* 2019;2019:9374607. doi: 10.1155/2019/9374607

52. Procópio ALF, da Silva RA, Maciel JG, Sugio CYC, Soares S, Urban VM, et al. Antimicrobial and cytotoxic effects of denture base acrylic resin impregnated with cleaning agents after long-term immersion. *Toxicol In Vitro* 2018;52:8-13. doi: 10.1016/j.tiv.2018.05.012

53. Cai X, Lin M, Tan S, Mai W, Zhang Y, Liang Z, et al. The use of polyethyleneimine-modified reduced graphene oxide as a substrate for silver nanoparticles to produce a material with lower cytotoxicity and long-term antibacterial activity. *Carbon* 2012;50(10):3407-15. doi: 10.1016/j.carbon.2012.02.002

54. Wu T, Xie AG, Tan SZ, Cai X. Antimicrobial effects of quaternary phosphonium salt intercalated clay minerals on *Escherichia coli* and *Staphylococcus aureus*. *Colloids Surf B Biointerfaces* 2011;86(1):232-6. doi: 10.1016/j.colsurfb.2011.04.009

55. Chen T, Chen L, Li H, Chen Y, Guo H, Shu Y, et al. Design and in vitro evaluation of a novel poly(methacrylic acid)/metronidazole antibacterial nanogel as an oral dosage form. *Colloids Surf B Biointerfaces* 2014;118:65-71. doi: 10.1016/j.colsurfb.2014.02.011

56. Craig RG, Sakaguchi RL, Ferracane J, Powers JM. *Restorative Dental Materials*. 14th ed. St Louis: Mosby; 2002. p. 478.

57. Consani RL, Polli RL, Nogueira MC, Correr AB, Mesquita MF. Effect of polymerization cycles on gloss, roughness, hardness and impact strength of acrylic resins. *Braz Dent J* 2016;27(2):176-80. doi: 10.1590/0103-6440201600733